My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  alliance managers  partners  partner  alliance manager  partnerships  ecosystem  The Rhythm of Business  partnership  Jan Twombly  governance  biopharma  Strategic Alliance Magazine  Eli Lilly and Company  Vantage Partners  IoT  strategy  ASAP BioPharma Conference  healthcare  IBM  NetApp  2015 ASAP Global Alliance Summit  Cisco  communication  innovation  Strategic Alliances 

Accelerating Medicines and Jump-Starting Treatments: Public-Private Partnerships Enlist Takeda and Other Biopharma Companies in the Fight Against Serious Diseases

Posted By Hugh Rauscher, Friday, January 31, 2020

As the healthcare and biopharma ecosystem expands and diversifies, the public-private partnership model offers an important sphere of collaboration between biopharma companies, medical institutions, patient advocacy foundations, and governmental entities. Biopharma companies—many ASAP members among them—are increasingly getting involved with nonprofits, foundations, and other organizations to tackle the toughest diseases, and that includes ASAP global member Takeda Pharmaceuticals.

Takeda is a participant in approximately 80 large-scale collaborations between public and private entities designed to address significant health issues. The majority of these collaborations are around researching and developing new treatments. “We look to get involved where we can add value and where there is value to Takeda,” said Sean Breen, head of global science advocacy and public-private partnerships at Takeda. “In particular, we look for partnerships where patients and patient organizations have a voice in development and can help all the stakeholders understand what patients need.”

Two of the most significant public-private partnership models are the EU-sponsored Innovative Medicines Initiative (IMI) and the US-centered Accelerating Medicines Partnership (AMP).

Launched in 2008, the IMI is sponsored by the Directorate General for Research and Innovation of the European Commission. The IMI brings together medical institutions, academia, foundations, and industry with the aim of removing research bottlenecks in drug development. According to the IMI website, its €5 billion budget makes it the largest biomedical public-private partnership in the world. 

The AMP is a public-private partnership between the National Institutes of Health, the US Food and Drug Administration, and multiple biopharmaceutical and life science companies and nonprofit organizations. The AMP was launched in February 2014, with projects in three disease areas: Alzheimer’s, type 2 diabetes, and the autoimmune disorders of rheumatoid arthritis and lupus. In January 2018, an AMP project on Parkinson’s disease was also launched with nine partners. The partnership seeks to identify and validate promising biological targets for therapeutics and ultimately increase the number of new diagnostics and therapies for patients while reducing the time and cost of developing them.

“Increasingly, we are seeing regulatory and governmental authorities keen to foster collaboration in areas such as identifying biomarkers and translational research, especially around rare diseases,” said Breen. “Our people learn a lot from being involved in an effort with other world experts.”

There are important differences in the approach and mindset required when working alongside, in many cases, dozens of other biopharma companies that have been brought in to lend expertise. In such cases, Takeda does not have direct control over the objective, the data, or the intellectual property. “Sometimes we have a financial investment, but more often our ability to exercise influence depends on what we are contributing, whether that be know-how or data,” said Breen.

“As participants in these public-private partnerships, we need to understand the problem from the perspective of other stakeholders and work together for mutual benefit. This requires a flexible, adaptive mindset and not everybody can be successful.”

Takeda is not alone in these public-private partnerships. Other ASAP members that are part of AMP include global members Janssen, Lilly, and Merck, and corporate members Celgene, GlaxoSmithKline, Pfizer, and Sanofi. This promises to be an important area of expanding cooperation and collaboration between multiple entities, public and private, so expect to hear more about these disease-fighting efforts.

Tags:  Accelerating Medicines  Accelerating Medicines Partnership (AMP)  and Merck  Celgene  collaborations  GlaxoSmithKline  Innovative Medicines Initiative (IMI)  Janssen  Lilly  Pfizer  Public-Private Partnerships  Sanofi 

Share |
PermalinkComments (0)
 

An Unambiguous Call to Action: Preview the Q1 2017 Strategic Alliance Magazine

Posted By John W. DeWitt, Saturday, February 11, 2017

From the cover to The Close, the Q1 2017 issue of Strategic Alliance Magazine tackles the critical topics that matter in today’s increasingly complex collaborations—and serves as a call to action for partnering executives to step out of their comfort zone, sound the call for professional alliance management, and continuously build their organizations’ capability to collaborate everywhere. For example, in our regular column “The Close,” I share a recent conversation with top Cisco executive and collaboration leader Ron Ricci. While “comfort with ambiguity” is an oft-cited trait of alliance executives, I argue (with support from Ron) that there’s nothing ambiguous about your CEO recognizing that digitization demands collaboration if your company is to succeed. Get a jump start reading this issue—full text of “The Close” follows below.

“THE CLOSE: An Unambiguous Call to Action,” from Q1 2017 Strategic Alliance Magazine

In Genevieve Fraser’s Q1 2017 Member Spotlight on Celgene, she and Jeremy Ahouse, CSAP, PhD, discuss how his alliance team includes “the kinds of people who can live with ambiguity and difference even as they get things done.” I’ve often heard comfort with ambiguity cited as an important trait of partnering executives. I got to thinking: Do I know any “ambiguous” alliance executives?

Most partnering professionals I know strike me as grounded, clear-as-a-bell communicators who don’t hesitate to share their point of view and who often can be very directive. I surmise that it’s precisely a lack of personal ambiguity that helps alliance execs lead amidst ambiguity. In a nutshell, it takes confidence to collaborate.

You feel that confidence within Ron Ricci, co-author of The Collaboration Imperative and a longtime Cisco senior executive focused on collaboration as an organizational capability, who joined a 90-minute conference call with ASAP’s advisory board in January. Ricci and Norma Watenpaugh, CSAP, principal of Phoenix Consulting Group, discussed the just-published ISO 44001, the International Standards Organization’s standard for “collaborative business relationship management systems.” (See in-depth coverage forthcoming in eSAM Plus, ASAP blogs, and future Strategic Alliance Magazine articles.) Ricci believes the ISO standard—which aligns to ASAP’s alliance management frameworks—will help propagate a common language for business collaboration, inside and among organizations. Ricci and the many leaders he interacts with see partnering and collaborative ability as central to grappling with the pace of a rapidly digitizing world.

“I spend all day long talking to senior executives of diverse governments and companies around the world about their collaboration opportunities,” says Ricci, vice president of customer experience services at Cisco, whom I spoke to recently. “Speed is the most important thing they need to move their businesses [according to] every leader I’ve met with over the last five years on this topic of collaboration. And companies see collaboration as the means to get speed.”

Talking to Ricci is an unambiguous look into how the C-suite views partnering and collaboration today—and the opportunity this represents for alliance management.

“Digitization and the ability to connect anything has taken the notion of speed and actually made it a potential carnivore of companies,” Ricci explains. “Take the technology trend of standardization and connect to the broader business trend of digitization—now we have a market moving almost at the pace of Moore’s Law. In 18 to 24 months the way you make money serving your customers can evolve. … So the way organizations collaborate and work together might need to be the most important capability they need to survive in the 21st century.”

This is an unmistakable call to action for all alliance professionals. It’s time to evangelize the value of this profession like never before. Recent ASAP, Vantage Partners, and other studies present unambiguous data on how professional alliance management drives success and financial performance of partnerships. As exemplified by our cover story, “The Partner-Everywhere Imperative: A Practitioner’s Guide,” and numerous sessions at ASAP conferences, the ASAP community is on the forefront of extending and adapting alliance management frameworks, practices, and tools to the new, increasingly complex collaborations that now proliferate across industries and sectors.

“How do you survive in a world where risk is growing faster than growth?” a Fortune 500 CEO recently asked Ricci. “You have to operate at an uncommon level of speed, adaptability, and flexibility,” Ricci responds. “And if there’s a better way to do that than collaboration, please tell me.”

And if there’s a better resource for collaboration success than your alliance team, the ASAP community, and the alliance management profession, please tell me.

Tags:  alliance executives  alliances  ASAP Conferences  Celgene  collaboration  C-suite  Fortune500  Jeremy Ahouse  Partner-Everywhere  Ron Ricci  Strategic Alliance Magazine  The Collaboration Imperative  Vantage Partners 

Share |
PermalinkComments (0)
 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630